CYP19A1 and breast carcinoma: Another randomized, double-blind, placebo-controlled pilot study investigated the effects of supplementation with 4 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for three months in postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy [32].